214 related articles for article (PubMed ID: 29993139)
21. Salivary duct carcinoma: the predominance of apocrine morphology, prevalence of histologic variants, and androgen receptor expression.
Williams L; Thompson LD; Seethala RR; Weinreb I; Assaad AM; Tuluc M; Ud Din N; Purgina B; Lai C; Griffith CC; Chiosea SI
Am J Surg Pathol; 2015 May; 39(5):705-13. PubMed ID: 25871467
[TBL] [Abstract][Full Text] [Related]
22. [Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma].
Otsuka K; Imanishi Y; Habu N; Sato Y; Shigetomi S; Fujii R; Sakamoto K; Tomita T; Fujii M; Kameyama K; Ogawa K
Nihon Jibiinkoka Gakkai Kaiho; 2013 Sep; 116(9):1024-32. PubMed ID: 24191589
[TBL] [Abstract][Full Text] [Related]
23. Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.
Udager AM; Chiosea SI
Head Neck Pathol; 2017 Sep; 11(3):288-294. PubMed ID: 28321773
[TBL] [Abstract][Full Text] [Related]
24. Genomic alteration in rare subtype of sarcomatoid salivary duct carcinoma.
Jeong JS; Cho KJ; Kim D; Lee YS; Song JS
Pathol Res Pract; 2021 Dec; 228():153678. PubMed ID: 34781210
[TBL] [Abstract][Full Text] [Related]
25. Increased expression of USP22 is associated with disease progression and patient prognosis of salivary duct carcinoma.
Piao S; Ma J; Wang W; Liu Y; Zhang M; Chen H; Guo F; Zhang B; Guo F
Oral Oncol; 2013 Aug; 49(8):796-801. PubMed ID: 23664741
[TBL] [Abstract][Full Text] [Related]
26. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.
Boon E; Bel M; van Boxtel W; van der Graaf WTA; van Es RJJ; Eerenstein SEJ; Baatenburg de Jong RJ; van den Brekel MWM; van der Velden LA; Witjes MJH; Hoeben A; Willems SM; Bloemena E; Smit LA; Oosting SF; ; Jonker MA; Flucke UE; van Herpen CML
Int J Cancer; 2018 Aug; 143(4):758-766. PubMed ID: 29492965
[TBL] [Abstract][Full Text] [Related]
27. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK
Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966
[TBL] [Abstract][Full Text] [Related]
28. The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation.
Ettl T; Schwarz-Furlan S; Haubner F; Müller S; Zenk J; Gosau M; Reichert TE; Zeitler K
Oral Oncol; 2012 Sep; 48(9):822-30. PubMed ID: 22445095
[TBL] [Abstract][Full Text] [Related]
29. Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations.
Wang K; Russell JS; McDermott JD; Elvin JA; Khaira D; Johnson A; Jennings TA; Ali SM; Murray M; Marshall C; Oldham DS; Washburn D; Wong SJ; Chmielecki J; Yelensky R; Lipson D; Miller VA; Stephens PJ; Serracino HS; Ross JS; Bowles DW
Clin Cancer Res; 2016 Dec; 22(24):6061-6068. PubMed ID: 27334835
[TBL] [Abstract][Full Text] [Related]
30. Molecular and biomarker analyses of salivary duct carcinomas: comparison with mammary duct carcinoma.
Hoang MP; Callender DL; Sola Gallego JJ; Huang Z; Sneige N; Luna MA; Batsakis JG; El-Naggar AK
Int J Oncol; 2001 Oct; 19(4):865-71. PubMed ID: 11562768
[TBL] [Abstract][Full Text] [Related]
31. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature.
Fan CY; Wang J; Barnes EL
Am J Surg Pathol; 2000 Apr; 24(4):579-86. PubMed ID: 10757407
[TBL] [Abstract][Full Text] [Related]
32. Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.
van Boxtel W; Verhaegh GW; van Engen-van Grunsven IA; van Strijp D; Kroeze LI; Ligtenberg MJ; van Zon HB; Hendriksen Y; Keizer D; van de Stolpe A; Schalken JA; van Herpen CM
Int J Cancer; 2020 Jun; 146(11):3196-3206. PubMed ID: 31745978
[TBL] [Abstract][Full Text] [Related]
33. The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities.
Alame M; Cornillot E; Cacheux V; Tosato G; Four M; De Oliveira L; Gofflot S; Delvenne P; Turtoi E; Cabello-Aguilar S; Nishiyama M; Turtoi A; Costes-Martineau V; Colinge J
Theranostics; 2020; 10(10):4383-4394. PubMed ID: 32292502
[No Abstract] [Full Text] [Related]
34. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma.
Fan CY; Melhem MF; Hosal AS; Grandis JR; Barnes EL
Arch Otolaryngol Head Neck Surg; 2001 Sep; 127(9):1075-9. PubMed ID: 11556855
[TBL] [Abstract][Full Text] [Related]
35. Molecular characterization of apocrine salivary duct carcinoma.
Chiosea SI; Williams L; Griffith CC; Thompson LD; Weinreb I; Bauman JE; Luvison A; Roy S; Seethala RR; Nikiforova MN
Am J Surg Pathol; 2015 Jun; 39(6):744-52. PubMed ID: 25723113
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical Reactivity of Prostate-Specific Markers for Salivary Duct Carcinoma.
Takada N; Nishida H; Oyama Y; Kusaba T; Kadowaki H; Arakane M; Wada J; Urabe S; Daa T
Pathobiology; 2020; 87(1):30-36. PubMed ID: 31865345
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.
Guiu S; Mollevi C; Charon-Barra C; Boissière F; Crapez E; Chartron E; Lamy PJ; Gutowski M; Bourgier C; Romieu G; Simony-Lafontaine J; Jacot W
Br J Cancer; 2018 Jul; 119(1):76-79. PubMed ID: 29880907
[TBL] [Abstract][Full Text] [Related]
38. [Salivary duct carcinomas comprise phenotypically and genotypically diverse high grade neoplasms].
Hungermann D; Korsching E; Bürger H; Röser K; Löning T; Herbst H
Verh Dtsch Ges Pathol; 2006; 90():168-76. PubMed ID: 17867594
[TBL] [Abstract][Full Text] [Related]
39. Salivary duct carcinoma: new developments--morphological variants including pure in situ high grade lesions; proposed molecular classification.
Simpson RH
Head Neck Pathol; 2013 Jul; 7 Suppl 1(Suppl 1):S48-58. PubMed ID: 23821208
[TBL] [Abstract][Full Text] [Related]
40. Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations.
Luk PP; Weston JD; Yu B; Selinger CI; Ekmejian R; Eviston TJ; Lum T; Gao K; Boyer M; O'Toole SA; Clark JR; Gupta R
Head Neck; 2016 Apr; 38 Suppl 1():E1838-47. PubMed ID: 26699379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
